Lanthanum carbonate treatment, for up to 6 years, is not associated with adverse effects on the liver in patients with chronic kidney disease Stage 5 receiving hemodialysis

Abstract

Hepatic biochemical tests for alanine transaminase, aspartate aminotransferase, alkaline phosphatase and bilirubin were performed in four initial clinical trials with lanthanum carbonate. Overall, there was no increase in the incidence of adverse events associated with the liver reported after up to 6 years of treatment when compared with the results of the initial studies.

There was no evidence of adverse effects of lanthanum carbonate on the liver in patients who received treatment for up to 6 years.